EMA 发布固体口服制剂共处理辅料问答文件
EMA: Q&A 'Co-Processed Excipients' published
EMA 于2026年1月在官网发布固体口服制剂(人用与兽用)共处理辅料问答文件。文件按风险导向将共处理辅料分为 A(高风险)、B(中风险)、C(低风险)三类,并分别说明监管申报资料要求,另附风险因素影响排序表和决策树。该问答的意见征集截止于2024年12月31日,收到的意见已以表格形式汇总公布。
材料列出问答文件的章节结构及 A/B/C 风险分级与对应申报资料要求,可帮助读者定位共处理辅料的合规要点。
In January 2026, the Q&A document 'Questions and Answers regarding co-processed excipients used in solid oral dosage forms (H & V)' was finally published on the EMA (European Medicines Agency) website. Comments on this list of questions and answers could be submitted until 31 December 2024, as reported in EMA: Comments on Q&As for 'Co-processed Excipients' possible. The comments received can also be viewed here. The document 'Overview of comments received on Q&A regarding co-processed excipients used in solid oral dosage forms H and V' contains these comments in tabular form.The Q&A refers to dosage forms for human and veterinary medicinal products and points out that co-processed excipients not only have advantages but can also pose a higher risk compared to excipients used individually.The document consists of the following chapters and appendices:Introduction1. What is a "co-processed excipient" in the context of these Q&As?2. How to categorise a co-processed excipient in a finished product using a risk-based approach?3. What are the regulatory dossier requirements to a co-processed excipient? 3.1. The risk assessment concludes a category C (low risk CoPE) 3.2. The risk assessment concludes a category B (medium risk CoPE) 3.3. The risk assessment concludes a category A (high risk CoPE)Annex I: Risk factors and impact ranking tableAnnex II: Decision tree on risk factor and impact ranking of CoPE with regard to the CQAs of finished productIn addition, Annex I provides an example for each category (A, B, C).Please see the EMA website for the complete list of questions and answers, 'Questions and Answers regarding co-processed excipients used in solid oral dosage forms (H & V)', and the corresponding comments.
来源:ECA GMP News · gmp-compliance.org